Preclinical studies demonstrate CDK4/6 knockout selectively inhibits tumor growth while sparing normal cells, underscoring its therapeutic potential (Moreno et al., 2025; Zhang et al., 2025). This evidence concerns the gene CDK4 and neoplasm.